Synlogic announced the decision to discontinue Synpheny-3, its ongoing pivotal study of labafenogene marselecobac as a potential treatment for phenylketonuria. As a result, Synlogic’s management and its board have made the decision to evaluate strategic options for the company. The decision to end Synpheny-3 is based on results of an internal review in advance of an upcoming independent Data Monitoring Committee assessment, which indicated the trial was unlikely to meet its primary endpoint, the company said in a statement.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SYBX:
- Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
- Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
- Synlogic reports publication of prelinical, clinical data for SYNB1353
- Synlogic Provides Corporate Update and Outlook for 2024
- Synlogic provides corporate update, outlook for 2024
